• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

254964-60-8 (Tasquinimod)

1

Identification

Tasquinimod Tasquinimod
Name Tasquinimod
Formula C20H17F3N2O4
MW 406.36
CAS No. 254964-60-8
EINECS
Smiles O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2OC)N(C)C3=CC=C(C(F)(F)F)C=C3
Synonyms ABR-215050;ABR215050;ABR 215050; 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-(4-(trifluoromethyl)phenyl)-1,2-dihydroquinoline-3-carboxamide
InChI InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
2

Introduction

Tasquinimod(ABR-215050) is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities.

Background Information

A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. ......by AOBIOUS INC
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.
......by AdooQ BioScience, LLC
Description ......by Apexbio Technology LLC
Tasquinimod is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been sh ......by BOC Sciences
Tasquinimod is an oral allosteric modulator of HDAC4 with a Kd of 10–30 nM for the regulatory Zn2+ binding domain of HDAC4. ......by MedChemexpress Co., Ltd.
Tasquinimod, also known as ABR215050, is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts. ......by MedKoo Biosciences, Inc.
An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM; inhibits colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1α.Prostate cancerPhase 3 Clinical ......by ProbeChem
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. Phase 3. ......by Selleck Chemicals LLC
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. Phase 3. ......by Target Molecule Corp.
3

Protocol(Only for Reference)

Cell Experiment

Cell lines LNCaP cells
Conditions 24 h; 50 μM
Method Generated microarray data based on four separate biological replicates showed a drug-induced effect of 50μM tasquinimod on gene expression in LNCaP cells when cultured in vitro for 24 h. The expression data achieved by RT-PCR were consistent with the microarray analysis data with a significant up-regulation of THBS1, GDF15 and CYP1A1 whereas CXCR4 and AGER1 did not change expression significantly.
Source Apexbio Technology LLC

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white Solid EBNumber:EB000024264

Storage condition

Store at -20°C by Apexbio Technology LLC

Solubility

Soluble in DMSO > 10 mM by Apexbio Technology LLC
DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Tasquinimod Active Biotech AB Hormone refractory prostate cancer 2011/3/31 2016/1/31 Phase 3 Clinical
Tasquinimod Ipsen Hormone refractory prostate cancer 2013/1/31 2016/2/29 Phase 2 Clinical
Tasquinimod Ipsen Metastatic prostate cancer 2013/1/31 2016/2/29 Phase 2 Clinical
Tasquinimod Active Biotech AB Hormone refractory prostate cancer 2007/8/10 2012/7/31 Phase 2 Clinical
Tasquinimod Duke University Hormone refractory prostate cancer 2012/1/31 2015/3/31 Phase 1 Clinical
Tasquinimod Active Biotech Research AB Prostate tumor 2009/1/31 2009/3/31 Phase 1 Clinical
Tasquinimod - Phase 3
7

Safety Data of Tasquinimod

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AOBIOUS INC USA
AdooQ BioScience, LLC USA
Apexbio Technology LLC USA
Ark Pharm, Inc. USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD120();10mg/USD190() USA
Cayman Chemical Company USA
MedChemexpress Co., Ltd. 5mg/USD120();10mg/USD190() USA
MedKoo Biosciences, Inc. USA
ProbeChem
Selleck Chemicals LLC USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD120();10mg/USD190() China
Target Molecule Corp. 5mg/USD134() USA
10

Related Products

Other Forms of 254964-60-8

Name CAS No Formula MW

Recommended Compounds in HDAC

Name CAS No Formula MW
Nexturastat A 1403783-31-2 C19H23N3O3 341.4
4SC-202 (free base) 910462-43-0 C23H21N5O3S 447.51
Citarinostat 1316215-12-9 C24H26ClN5O3 467.9479
Tenovin 6 (Hydrochloride) 1011301-29-3 C25H35ClN4O2S 491.09
Sodium Butyrate 156-54-7 C4H7NaO2 110.087
Valproic acid (sodium salt) 1069-66-5 C8H15NaO2 166.19
RGFP966 1357389-11-7 C21H19FN4O 362.4
Resminostat (hydrochloride) 1187075-34-8 C16H20ClN3O4S 385.87
TMP195 1314891-22-9 C23H19F3N4O3 456.4172
TMP269 1314890-29-3 C25H21F3N4O3S 514.52
Benzenebutyric acid 1821-12-1 C10H12O2 164.2011
Parthenolide 20554-84-1 C15H20O3 248.32
Tubastatin-A 1252003-15-8 C20H21N3O2 335.4
Sulforaphane 4478-93-7 C6H11NOS2 177.29
Dacinostat 404951-53-7 C22H25N3O3 379.45
Chidamide 743420-02-2 C22H19FN4O2 390.41
CUDC-907 1339928-25-4 C23H24N8O4S 508.55
Sirtinol 410536-97-9 C26H22N2O2 394.47
M344 251456-60-7 C16H25N3O3 307.39
Tubacin 537049-40-4 C41H43N3O7S 721.86

Recommended Compounds in Same Indication

Name CAS No Formula MW
TAK-700 (R-form) 752243-39-3 C18H17N3O2 307.35
Olaparib 763113-22-0 C24H23FN4O3 434.46
KX2-391 897016-82-9 C26H29N3O3 431.53
AT-101 90141-22-3 C30H30O8 518.55
Bicalutamide 90357-06-5 C18H14F4N2O4S 430.37
Enzalutamide 915087-33-1 C21H16F4N4O2S 464.44
Tivozanib 475108-18-0 C22H19ClN4O5 454.86
Orteronel 566939-85-3 C18H17N3O2 307.35
Linsitinib 867160-71-2 C26H23N5O 421.49
Fenretinide 65646-68-6 C26H33NO2 391.55
Leuprolide (Acetate) 74381-53-6 C61H88N16O14 1269.45
Retaspimycin 857402-23-4 C31H45N3O8 587.7
Retaspimycin (Hydrochloride) 857402-63-2 C31H46ClN3O8 624.17
Bafetinib 859212-16-1 C30H31F3N8O 576.6154
AT13387 912999-49-6 C24H31N3O3 409.52
Ganetespib 888216-25-9 C20H20N4O3 364.4
Orteronel (racemate) 426219-18-3 C18H17N3O2 307.3465
TAK-700 (salt) 426219-53-6 C28H28N4O7 532.54
TOK-001 851983-85-2 C26H32N2O 388.55
RO4929097 847925-91-1 C22H20F5N3O3 469.4
11

Route of Synthesis

12

References

[1]. Olsson A, Bj?rk A, Vallon-Christersson J et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107.

[2]. Jennbacken, Karin; Welen, Karin; Olsson, Anders et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate (Hoboken, NJ, United States) (2012), 72(8), 913-924.

[3]. Dalrymple, Susan L.; Becker, Robyn E.; Zhou, Haoming et al. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate (Hoboken, NJ, United States) (2012), 72(6), 638-648.

[4]. Isaacs, John T. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion on Investigational Drugs (2010), 19(10), 1235-1243.

[5]. Bratt, O.; Haeggman, M.; Ahlgren, G. et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer (2009), 101(8), 1233-1240.

[6]. Clinical Trials

Protocol Reference

[1] Olsson A, Björk A, Vallon-Christersson J, et al. Research Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors[J]. 2010.

[2] Jennbacken K, Welen K, Olsson A, et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline‐3‐carboxamide tasquinimod (ABR‐215050)[J]. The Prostate, 2012, 72(8): 913-924.

......by Apexbio Technology LLC
13

More Information

Tasquinimod

Tags: buy 254964-60-8 IC50 | 254964-60-8 price | 254964-60-8 cost | 254964-60-8 solubility | 254964-60-8 purchase | 254964-60-8 manufacturer | 254964-60-8 research buy | 254964-60-8 order | 254964-60-8 MSDS | 254964-60-8 chemical structure | 254964-60-8 Storage condition | 254964-60-8 molecular weight | 254964-60-8 mw | 254964-60-8 datasheet | 254964-60-8 supplier | 254964-60-8 cell line | 254964-60-8 NMR | 254964-60-8 MS | 254964-60-8 IR | 254964-60-8 solubility | 254964-60-8 Safe information | 254964-60-8 Qc and Spectral Information | 254964-60-8 Clinical Information | 254964-60-8 Clinical Trial | 254964-60-8 Route of Synthesis | 254964-60-8 storage condition | 254964-60-8 diseases and conditions | 254964-60-8 flash point | 254964-60-8 boiling point | 254964-60-8 melting point | 254964-60-8 storage condition | 254964-60-8 brand